通过新辅助化疗优化非小细胞肺癌 CD103+CD8+ 组织驻留记忆 T 细胞的空间免疫格局

IF 6.6 2区 医学 Q1 Medicine
Cellular Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-19 DOI:10.1007/s13402-024-00980-4
Guanqun Yang, Mengyu Hu, Siqi Cai, Chaozhuo Li, Liying Yang, Miaoqing Zhao, Hongbiao Jing, Ligang Xing, Xiaorong Sun
{"title":"通过新辅助化疗优化非小细胞肺癌 CD103+CD8+ 组织驻留记忆 T 细胞的空间免疫格局","authors":"Guanqun Yang, Mengyu Hu, Siqi Cai, Chaozhuo Li, Liying Yang, Miaoqing Zhao, Hongbiao Jing, Ligang Xing, Xiaorong Sun","doi":"10.1007/s13402-024-00980-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy (NAC) combined with immunotherapy is increasingly used in non-small cell lung cancer (NSCLC). Tissue-resident memory T (T<sub>RM</sub>) cells are the primary subset responding to anti-cancer immunity. However, the immunomodulatory effects of NAC on T<sub>RM</sub> cells remain unknown.</p><p><strong>Methods: </strong>We established two NSCLC cohorts including patients undergoing upfront surgery (US) and NAC followed by surgery. Beyond the unpaired comparison between the US cohort (n = 122) and NAC cohort (n = 141) with resection samples, 58 matched pre-NAC biopsy samples were available for paired comparisons. Using multiplex immunofluorescence, we characterized T<sub>RM</sub> cells (CD103<sup>+</sup>CD8<sup>+</sup>) and four heterogeneous T<sub>RM</sub> subsets, including naive T<sub>RM1</sub> (PD-1<sup>-</sup>Tim-3<sup>-</sup>), pre-exhausted T<sub>RM2</sub> (PD-1<sup>+</sup>Tim-3<sup>-</sup>), T<sub>RM3</sub> (PD-1<sup>-</sup>Tim-3<sup>+</sup>), and terminally exhausted T<sub>RM4</sub> (PD-1<sup>+</sup>Tim-3<sup>+</sup>). Cell density, cytotoxicity, and two spatial features were defined to evaluate the effect of NAC on T<sub>RM</sub> subsets.</p><p><strong>Results: </strong>The cell densities, infiltration scores, and cancer-cell proximity scores of T<sub>RM</sub> cells, especially T<sub>RM1&2</sub> subsets, were significantly increased after NAC and associated with better prognosis of patients. In Contrast, no significant change was observed in the T<sub>RM4</sub> subset, which was associated with poor prognosis. Besides, the cytotoxicity of T<sub>RM</sub> subsets was unaltered after NAC. Compared with patients without major pathologic response (MPRs), patients with MPR had higher densities of T<sub>RM1&2</sub> subsets and higher cancer-cell proximity scores of T<sub>RM2&3</sub> subsets. Furthermore, increased density of CD31 + cancer microvessels was positively associated with both T<sub>RM</sub> and T<sub>non-RM</sub> cells after NAC.</p><p><strong>Conclusions: </strong>NAC may remodel the cell density and spatial distribution of T<sub>RM</sub> subsets, which is associated with favorable therapeutic effect and prognosis in patients with NSCLC.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":" ","pages":"1957-1971"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimizing the spatial immune landscape of CD103<sup>+</sup>CD8<sup>+</sup> tissue-resident memory T cells in non-small cell lung cancer by neoadjuvant chemotherapy.\",\"authors\":\"Guanqun Yang, Mengyu Hu, Siqi Cai, Chaozhuo Li, Liying Yang, Miaoqing Zhao, Hongbiao Jing, Ligang Xing, Xiaorong Sun\",\"doi\":\"10.1007/s13402-024-00980-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Neoadjuvant chemotherapy (NAC) combined with immunotherapy is increasingly used in non-small cell lung cancer (NSCLC). Tissue-resident memory T (T<sub>RM</sub>) cells are the primary subset responding to anti-cancer immunity. However, the immunomodulatory effects of NAC on T<sub>RM</sub> cells remain unknown.</p><p><strong>Methods: </strong>We established two NSCLC cohorts including patients undergoing upfront surgery (US) and NAC followed by surgery. Beyond the unpaired comparison between the US cohort (n = 122) and NAC cohort (n = 141) with resection samples, 58 matched pre-NAC biopsy samples were available for paired comparisons. Using multiplex immunofluorescence, we characterized T<sub>RM</sub> cells (CD103<sup>+</sup>CD8<sup>+</sup>) and four heterogeneous T<sub>RM</sub> subsets, including naive T<sub>RM1</sub> (PD-1<sup>-</sup>Tim-3<sup>-</sup>), pre-exhausted T<sub>RM2</sub> (PD-1<sup>+</sup>Tim-3<sup>-</sup>), T<sub>RM3</sub> (PD-1<sup>-</sup>Tim-3<sup>+</sup>), and terminally exhausted T<sub>RM4</sub> (PD-1<sup>+</sup>Tim-3<sup>+</sup>). Cell density, cytotoxicity, and two spatial features were defined to evaluate the effect of NAC on T<sub>RM</sub> subsets.</p><p><strong>Results: </strong>The cell densities, infiltration scores, and cancer-cell proximity scores of T<sub>RM</sub> cells, especially T<sub>RM1&2</sub> subsets, were significantly increased after NAC and associated with better prognosis of patients. In Contrast, no significant change was observed in the T<sub>RM4</sub> subset, which was associated with poor prognosis. Besides, the cytotoxicity of T<sub>RM</sub> subsets was unaltered after NAC. Compared with patients without major pathologic response (MPRs), patients with MPR had higher densities of T<sub>RM1&2</sub> subsets and higher cancer-cell proximity scores of T<sub>RM2&3</sub> subsets. Furthermore, increased density of CD31 + cancer microvessels was positively associated with both T<sub>RM</sub> and T<sub>non-RM</sub> cells after NAC.</p><p><strong>Conclusions: </strong>NAC may remodel the cell density and spatial distribution of T<sub>RM</sub> subsets, which is associated with favorable therapeutic effect and prognosis in patients with NSCLC.</p>\",\"PeriodicalId\":9690,\"journal\":{\"name\":\"Cellular Oncology\",\"volume\":\" \",\"pages\":\"1957-1971\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cellular Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13402-024-00980-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-024-00980-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:非小细胞肺癌(NSCLC)越来越多地采用新辅助化疗(NAC)联合免疫疗法。组织驻留记忆 T(TRM)细胞是对抗癌免疫做出反应的主要亚群。然而,NAC对TRM细胞的免疫调节作用仍然未知:我们建立了两个 NSCLC 队列,包括接受前期手术(US)和接受 NAC 后再手术的患者。除了对US队列(122人)和NAC队列(141人)的切除样本进行非配对比较外,还提供了58份匹配的NAC前活检样本进行配对比较。我们使用多重免疫荧光鉴定了TRM细胞(CD103+CD8+)和四个异质性TRM亚群,包括天真TRM1(PD-1-Tim-3-)、衰竭前TRM2(PD-1+Tim-3-)、TRM3(PD-1-Tim-3+)和终末衰竭TRM4(PD-1+Tim-3+)。界定了细胞密度、细胞毒性和两个空间特征,以评估 NAC 对 TRM 亚群的影响:结果:NAC治疗后,TRM细胞,尤其是TRM1和TRM2亚群的细胞密度、浸润评分和癌细胞接近评分均显著增加,并与患者的预后改善相关。与此相反,TRM4 亚群则无明显变化,与预后不良有关。此外,TRM 亚群的细胞毒性在 NAC 后没有改变。与无重大病理反应的患者相比,重大病理反应患者的TRM1和TRM2亚群密度更高,TRM2和TRM3亚群的癌细胞接近度评分更高。此外,CD31 +癌微血管密度的增加与NAC后的TRM和Tnon-RM细胞均呈正相关:结论:NAC可重塑TRM亚群的细胞密度和空间分布,这与NSCLC患者的良好疗效和预后有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Optimizing the spatial immune landscape of CD103<sup>+</sup>CD8<sup>+</sup> tissue-resident memory T cells in non-small cell lung cancer by neoadjuvant chemotherapy.

Optimizing the spatial immune landscape of CD103+CD8+ tissue-resident memory T cells in non-small cell lung cancer by neoadjuvant chemotherapy.

Background: Neoadjuvant chemotherapy (NAC) combined with immunotherapy is increasingly used in non-small cell lung cancer (NSCLC). Tissue-resident memory T (TRM) cells are the primary subset responding to anti-cancer immunity. However, the immunomodulatory effects of NAC on TRM cells remain unknown.

Methods: We established two NSCLC cohorts including patients undergoing upfront surgery (US) and NAC followed by surgery. Beyond the unpaired comparison between the US cohort (n = 122) and NAC cohort (n = 141) with resection samples, 58 matched pre-NAC biopsy samples were available for paired comparisons. Using multiplex immunofluorescence, we characterized TRM cells (CD103+CD8+) and four heterogeneous TRM subsets, including naive TRM1 (PD-1-Tim-3-), pre-exhausted TRM2 (PD-1+Tim-3-), TRM3 (PD-1-Tim-3+), and terminally exhausted TRM4 (PD-1+Tim-3+). Cell density, cytotoxicity, and two spatial features were defined to evaluate the effect of NAC on TRM subsets.

Results: The cell densities, infiltration scores, and cancer-cell proximity scores of TRM cells, especially TRM1&2 subsets, were significantly increased after NAC and associated with better prognosis of patients. In Contrast, no significant change was observed in the TRM4 subset, which was associated with poor prognosis. Besides, the cytotoxicity of TRM subsets was unaltered after NAC. Compared with patients without major pathologic response (MPRs), patients with MPR had higher densities of TRM1&2 subsets and higher cancer-cell proximity scores of TRM2&3 subsets. Furthermore, increased density of CD31 + cancer microvessels was positively associated with both TRM and Tnon-RM cells after NAC.

Conclusions: NAC may remodel the cell density and spatial distribution of TRM subsets, which is associated with favorable therapeutic effect and prognosis in patients with NSCLC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cellular Oncology
Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
10.40
自引率
1.50%
发文量
0
审稿时长
16 weeks
期刊介绍: The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信